CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Millions	Total	Total Stockholders' Equity	Common Stock	Capital In Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive (Loss) income	Treasury Stock	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2021			198,649
Beginning balance at Dec. 31, 2021	$ 16,103	$ 16,080	$ 33	$ 3,082	$ 23,086	$ 42	$ (10,163)	$ 23
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	2,820	2,821			2,821			(1)
Distribution from (to) noncontrolling interest holders, net	(1)							(1)
Sale of Gentiva Hospice	(11)							(11)
Acquisition	53							53
Other comprehensive loss	(1,509)	(1,509)				(1,509)
Common stock repurchases	(1,032)	(1,032)					(1,032)
Dividends and dividend equivalents	(301)	(301)			(301)
Stock-based compensation	173	173		173
Restricted stock unit vesting (in shares)			18
Restricted stock unit vesting	0			(31)			31
Stock option exercises	22	22		10			12
Ending balance (in shares) at Sep. 30, 2022			198,667
Ending balance at Sep. 30, 2022	16,317	16,254	$ 33	3,234	25,606	(1,467)	(11,152)	63
Beginning balance (in shares) at Jun. 30, 2022			198,667
Beginning balance at Jun. 30, 2022	15,510	15,490	$ 33	3,153	24,511	(1,051)	(11,156)	20
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,193	1,195			1,195			(2)
Distribution from (to) noncontrolling interest holders, net	3							3
Sale of Gentiva Hospice	(11)							(11)
Acquisition	53							53
Other comprehensive loss	(416)	(416)				(416)
Common stock repurchases	(4)	(4)					(4)
Dividends and dividend equivalents	(100)	(100)			(100)
Stock-based compensation	80	80		80
Restricted stock unit vesting	0			(3)			3
Stock option exercises	9	9		4			5
Ending balance (in shares) at Sep. 30, 2022			198,667
Ending balance at Sep. 30, 2022	16,317	16,254	$ 33	3,234	25,606	(1,467)	(11,152)	63
Beginning balance (in shares) at Dec. 31, 2022			198,667
Beginning balance at Dec. 31, 2022	15,370	15,311	$ 33	3,246	25,492	(1,304)	(12,156)	59
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	3,024	3,030			3,030			(6)
Distribution from (to) noncontrolling interest holders, net	7							7
Acquisition	(5)							(5)
Other comprehensive loss	(199)	(199)				(199)
Common stock repurchases	(1,011)	(1,011)					(1,011)
Dividends and dividend equivalents	(331)	(331)			(331)
Stock-based compensation	142	142		142
Restricted stock unit vesting (in shares)			23
Restricted stock unit vesting	0			(30)			30
Stock option exercises	7	7		4			3
Ending balance (in shares) at Sep. 30, 2023			198,690
Ending balance at Sep. 30, 2023	17,004	16,949	$ 33	3,362	28,191	(1,503)	(13,134)	55
Beginning balance (in shares) at Jun. 30, 2023			198,690
Beginning balance at Jun. 30, 2023	16,891	16,834	$ 33	3,313	27,468	(1,226)	(12,754)	57
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	830	832			832			(2)
Other comprehensive loss	(277)	(277)				(277)
Common stock repurchases	(383)	(383)					(383)
Dividends and dividend equivalents	(109)	(109)			(109)
Stock-based compensation	53	53		53
Restricted stock unit vesting	0			(3)			3
Stock option exercises	(1)	(1)		(1)
Ending balance (in shares) at Sep. 30, 2023			198,690
Ending balance at Sep. 30, 2023	$ 17,004	$ 16,949	$ 33	$ 3,362	$ 28,191	$ (1,503)	$ (13,134)	$ 55